Expert US stock capital allocation track record and investment grade assessment for management quality evaluation. We evaluate how well management has historically deployed capital to create shareholder value.
Ahead of its upcoming fiscal 2026 first-quarter earnings release, Regeneron Pharmaceuticals (NASDAQ: REGN) received a bullish rating update from TD Cowen, which lifted its 12-month price target 9.1% to $960 from $880 while reaffirming a Buy rating. The revision follows the U.S. FDA’s accelerated app
Regeneron Pharmaceuticals (REGN) - TD Cowen Ups Price Target Ahead of Fiscal Q1 Results, Supported by FDA Gene Therapy Approval - Most Discussed Stocks
REGN - Stock Analysis
3652 Comments
991 Likes
1
Talita
Trusted Reader
2 hours ago
Investor behavior indicates attention to both macroeconomic factors and individual stock fundamentals.
👍 209
Reply
2
Shauntal
Senior Contributor
5 hours ago
How do you even come up with this stuff? 🤯
👍 179
Reply
3
Jamiley
Active Contributor
1 day ago
Investor focus remains on fundamentals, with sentiment fluctuating in response to recent reports.
👍 217
Reply
4
Charnette
Power User
1 day ago
This feels like a clue to something bigger.
👍 131
Reply
5
Beatha
New Visitor
2 days ago
Who else is thinking deeper about this?
👍 238
Reply
© 2026 Market Analysis. All data is for informational purposes only.